














































CAPÍTULO REIVINDICATORIO MODIFICADO
(Segundo Examen de Fondo)










1. Un compuesto que se selecciona entre:










1 	2 	3 
4 	5 	6 
7 	8 	9 





































































































































































































y tautómeros del mismo, sales farmacéuticamente aceptables de los compuestos y tautómeros, y derivados deuterados de los compuestos, los tautómeros y las sales.

2. Un compuesto de Fórmula S3




un tautómero del mismo, una sal del compuesto o el tautómero o un derivado deuterado de cualquiera de los anteriores.

3. Un compuesto de Fórmula S6



un tautómero del mismo, una sal del compuesto o el tautómero o un derivado deuterado de cualquiera de los anteriores.

4. Un compuesto de Fórmula 32:



(Compuesto 32),

un tautómero del mismo, una sal farmacéuticamente aceptable del compuesto o el tautómero o un derivado deuterado de cualquiera de los anteriores.

5. Una composición que comprende al menos un compuesto seleccionado de los compuestos de acuerdo con la Reivindicación 1, tautómeros de los mismos, sales farmacéuticamente aceptables del compuesto o el tautómero y derivados deuterados de cualquiera de los anteriores, y al menos un vehículo farmacéuticamente aceptable.

6. Una Forma Cristalina A del Compuesto 32 de acuerdo con la Reivindicación 4, en donde la Forma Cristalina A se caracteriza por un difractograma de rayos X de polvo que tiene una señal a al menos dos valores de dos theta elegidos de $15,0 \pm 0,2$, $15,4 \pm 0,2$, $17,6 \pm 0,2$, y $20,4 \pm 0,2$; y por una calorimetría diferencial de barrido (DSC) que tiene un punto de fusión a 234°C .


7. Una composición que comprende la Forma cristalina A de acuerdo con la Reivindicación 6.

8. Una Forma Cristalina B del Compuesto 32 de acuerdo con la Reivindicación 4, en donde la Forma Cristalina B caracterizada por un difractograma de rayos X de polvo que tiene una señal a al menos dos valores de dos theta elegidos entre $10,0 \pm 0,2$, $11,3 \pm 0,2$, $12,2 \pm 0,2$, y $20,7 \pm 0,2$; y por una calorimetría diferencial de barrido (DSC) que tiene un punto de fusión a 246°C .


9. Una Forma Cristalina C del Compuesto 32 de acuerdo con la Reivindicación 4, caracterizada por un difractograma de rayos X de polvo que tiene una señal a al menos dos valores de dos theta elegidos entre $14,7 \pm 0,2$, $14,9 \pm 0,2$, y $17,0 \pm 0,2$; y por una calorimetría diferencial de barrido (DSC) que tiene un punto de fusión a 239°C .

10. Una composición que comprende la Forma cristalina A de acuerdo con la Reivindicación 6 y la Forma cristalina C de acuerdo con la Reivindicación 9, en donde la composición se caracteriza por un difractograma de rayos X de polvo que tiene una señal a al menos tres valores dos theta elegidos de $15,0 \pm 0,2$, $15,4 \pm 0,2$, $17,6 \pm 0,2$, $18,0 \pm 0,2$, y $20,3 \pm 0,2$; y por una calorimetría diferencial de barrido (DSC) que tiene un punto de fusión a 237°C .

11. Una sal monoclorhidrato del Compuesto 32 de acuerdo con la Reivindicación 4:



12. Un hemiclорhidrato hemihidratado del Compuesto 32 de acuerdo con la Reivindicación 4:



13. Una forma amorfa del Compuesto 32 de acuerdo con la Reivindicación 4.

14. Un solvato de etanol del Compuesto 32 de acuerdo con la Reivindicación 4, en donde el solvato de etanol del Compuesto 32 se caracteriza por un difractograma de rayos X de polvo que tiene una señal a al menos tres valores de dos theta elegidos de $9,8 \pm 0,2$, $11,3 \pm 0,2$, $20,5 \pm 0,2$ y $24,1 \pm 0,2$; y por una calorimetría diferencial de barrido (DSC) que tiene un punto de fusión a 248°C .

15. Una composición que comprende la forma amorfa de acuerdo con la Reivindicación 13, la sal monoclорhidrato de acuerdo con la Reivindicación 11, el hemiclорhidrato hemihidratado de acuerdo con la Reivindicación 12 y/o el solvato de etanol de la Reivindicación 14, y al menos un vehículo farmacéuticamente aceptable.
